Runben Biotechnology Valuation
Is 603193 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 603193 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 603193 (CN¥24.2) is trading above our estimate of fair value (CN¥10.38)
Significantly Below Fair Value: 603193 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603193?
Key metric: As 603193 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 603193's PE Ratio? | |
|---|---|
| PE Ratio | 32x |
| Earnings | CN¥306.18m |
| Market Cap | CN¥9.79b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.5x |
| Enterprise Value/EBITDA | 29.2x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does 603193's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.1x | ||
003006 Chongqing Baiya Sanitary Products | 38.9x | 26.1% | CN¥11.4b |
603983 Guangdong Marubi Biotechnology | 36.5x | 24.0% | CN¥12.4b |
300791 Sirio Pharma | 18.4x | 21.1% | CN¥6.2b |
600315 Shanghai Jahwa United | 42.6x | 27.5% | CN¥11.6b |
603193 Runben Biotechnology | 32x | 22.7% | CN¥9.8b |
Price-To-Earnings vs Peers: 603193 is good value based on its Price-To-Earnings Ratio (32x) compared to the peer average (34.7x).
Price to Earnings Ratio vs Industry
How does 603193's PE Ratio compare vs other companies in the CN Personal Products Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 603193 is good value based on its Price-To-Earnings Ratio (32x) compared to the CN Personal Products industry average (34.7x).
Price to Earnings Ratio vs Fair Ratio
What is 603193's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 603193's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥24.20 | CN¥30.17 +24.7% | 1.0% | CN¥30.68 | CN¥30.00 | n/a | 4 |
| Nov ’25 | n/a | CN¥30.17 0% | 1.0% | CN¥30.68 | CN¥30.00 | n/a | 4 |
| Oct ’25 | n/a | CN¥24.57 0% | 2.5% | CN¥25.00 | CN¥23.70 | n/a | 3 |
| Sep ’25 | n/a | CN¥24.57 0% | 2.5% | CN¥25.00 | CN¥23.70 | n/a | 3 |
| Aug ’25 | n/a | CN¥24.57 0% | 2.5% | CN¥25.00 | CN¥23.70 | n/a | 3 |
| Jul ’25 | n/a | CN¥23.77 0% | 7.3% | CN¥25.00 | CN¥21.30 | n/a | 3 |
| Jun ’25 | n/a | CN¥23.77 0% | 7.3% | CN¥25.00 | CN¥21.30 | n/a | 3 |
| May ’25 | n/a | CN¥23.77 0% | 7.3% | CN¥25.00 | CN¥21.30 | n/a | 3 |
| Apr ’25 | n/a | CN¥23.77 0% | 7.3% | CN¥25.00 | CN¥21.30 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
SYoung Group
CN¥5.0b
Engages in the research and development, production, and sale of cosmetic products in China.
300740
CN¥12.82
7D
-7.7%
1Y
-19.4%
Byhealth
CN¥21.7b
Develops and sells dietary supplements.
300146
CN¥12.90
7D
-5.4%
1Y
-28.4%
Sirio Pharma
CN¥6.2b
Operates as a contract manufacturer for dietary supplement industry worldwide.
300791
CN¥26.60
7D
-5.6%
1Y
2.7%